Fig. 3From: A phase III randomized trial of gantenerumab in prodromal Alzheimer’s diseaseMean (±SE) change from baseline in PET SUVr (cerebellar gray reference). *p < 0.01 vs placebo. PET SUVr Positron emission tomography standardized uptake value ratioBack to article page